Decades of relative inactivity and limited innovation have characterized a condition often labeled as "enigmatic." In her Guardian article, Gabrielle Jackson sheds light on the newfound optimism emerging from a deeper comprehension of this debilitating, chronic inflammatory disease.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.